GlassScriptPhysician profile
Marin F Xavier
NPI 1437211372
$918,724.57
in general payments reported to CMS, 2019-2025
93 companies · $116K in 2025
The $116K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $119K · 2021: $102K · 2022: $127K · 2023: $153K · 2024: $111K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $262K · Consulting Fee: $80K · Travel and Lodging: $23K · Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $261,863.67 |
| Consulting Fee | $80,192.50 |
| Travel and Lodging | $22,523.44 |
| Food and Beverage | $16,032.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $127,422.58 | 2019-2025 | Calquence, Imfinzi |
| Abbvie INC. | $110,664.38 | 2019-2025 | Venclexta, Epkinly |
| Incyte Corporation | $99,660.68 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Lilly USA, LLC | $96,859.60 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $87,035.14 | 2019-2025 | Reblozyl, Breyanzi, Opdivo |
| Beigene USA, INC. | $78,795.18 | 2020-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $55,847.19 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $24,082.38 | 2019-2024 | Iclusig |
| Seagen INC. | $22,552.62 | 2019-2023 | Adcetris, Tukysa |
| Genmab U.S., INC. | $16,983.18 | 2023-2025 | Epkinly |
| Genentech USA, INC. | $16,914.80 | 2019-2025 | Lunsumio, Tecentriq, Polivy |
| Adc Therapeutics America, INC. | $16,747.75 | 2021-2025 | |
| Kite Pharma, INC. | $15,647.22 | 2020-2025 | Yescarta |
| Acrotech Biopharma INC. | $13,058.99 | 2021-2025 | Beleodaq |
| Astellas Pharma US INC | $12,514.73 | 2019-2025 | Padcev, Cresemba |
Show all 91 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,367.24 | 2019-2025 | Ojjaara, Zejula, Jemperli |
| Epizyme, INC. | $11,765.56 | 2020-2021 | |
| Blueprint Medicines Corporation | $9,369.29 | 2021-2025 | Ayvakit |
| Beone Medicines USA, INC. | $9,252.08 | 2025 | Brukinsa |
| Aurobindo Pharma USA, INC. | $8,035.11 | 2019-2020 | |
| Gilead Sciences, INC. | $7,820.40 | 2019-2025 | Trodelvy |
| Geron Corporation | $6,584.17 | 2024-2025 | Imetelstat, Rytelo |
| Astrazeneca Uk Limited | $6,377.09 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $5,925.29 | 2019-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $4,583.08 | 2019-2025 | Tazverik, Onivyde, Somatuline Depot |
| Eli Lilly and Company | $4,499.92 | 2022-2025 | Verzenio |
| Janssen Biotech, INC. | $4,304.25 | 2019-2025 | Imbruvica, Darzalex, Erleada |
| Stemline Therapeutics INC. | $3,976.36 | 2022-2025 | Elzonris, Orserdu |
| Morphosys, US INC. | $3,582.98 | 2021-2023 | Monjuvi |
| Sobi, INC | $3,475.36 | 2023-2025 | |
| Taiho Oncology, INC. | $3,346.90 | 2019-2025 | |
| Verastem, INC. | $1,680.00 | 2020 | |
| Agios Pharmaceuticals, INC. | $1,663.23 | 2019-2025 | Pyrukynd |
| Cti Biopharma Corp. | $1,620.21 | 2022-2023 | Vonjo |
| Genentech, INC. | $1,588.63 | 2023-2024 | Venclexta, Columvi, Polivy |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2021 | |
| Merck Sharp & Dohme LLC | $1,222.70 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $900.17 | 2019-2025 | |
| Amgen INC. | $890.78 | 2019-2023 | Blincyto, Kyprolis |
| Teva Pharmaceuticals USA, INC. | $698.76 | 2019-2020 | |
| Pfizer INC. | $639.45 | 2019-2025 | |
| Eisai INC. | $463.64 | 2019-2025 | |
| Tg Therapeutics, INC. | $450.00 | 2021 | |
| Karyopharm Therapeutics INC. | $419.44 | 2020-2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $361.48 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $294.56 | 2019-2025 | |
| Clovis Oncology, INC. | $290.01 | 2019-2020 | |
| Pharmaessentia USA Corporation | $279.69 | 2023-2025 | Besremi |
| Exelixis INC. | $260.32 | 2019-2025 | Cabometyx |
| Array Biopharma INC | $249.41 | 2020-2025 | Mektovi, Braftovi, Xalkori |
| Foundation Medicine, INC. | $241.52 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $233.11 | 2020-2025 | Libtayo |
| Daiichi Sankyo INC. | $229.00 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Rigel Pharmaceuticals, INC. | $209.14 | 2019-2024 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.89 | 2019-2025 | |
| Puma Biotechnology, INC. | $168.99 | 2019-2024 | |
| Tersera Therapeutics LLC | $150.86 | 2021-2025 | Xermelo, Zoladex |
| Stryker Corporation | $149.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.89 | 2019-2025 | |
| Coherus Oncology, INC. | $113.96 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $112.04 | 2022-2025 | |
| Eusa Pharma (US) LLC | $88.23 | 2019 | |
| G1 Therapeutics, INC. | $82.43 | 2023 | Cosela |
| Deciphera Pharmaceuticals INC. | $80.96 | 2021-2024 | Qinlock |
| Dova Pharmaceuticals | $76.85 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $74.93 | 2020-2021 | |
| Secura Bio, INC. | $59.70 | 2020-2021 | |
| Emd Serono, INC. | $59.40 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $55.81 | 2019-2020 | |
| Iovance Biotherapeutics, INC. | $54.81 | 2025 | Amtagvi |
| Immunocore Limited | $54.42 | 2023 | Kimmtrak |
| Adaptive Biotechnologies Corporation | $54.23 | 2024-2025 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $51.72 | 2020-2023 | Odomzo |
| Jazz Pharmaceuticals INC. | $47.31 | 2020-2025 | |
| Springworks Therapeutics, INC. | $43.87 | 2025 | Ogsiveo |
| Otsuka America Pharmaceutical, INC. | $34.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.43 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $33.07 | 2019 | |
| Sumitomo Pharma America, INC. | $32.92 | 2024-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $28.03 | 2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $26.15 | 2020 | |
| Fennec Pharmaceuticals, INC. | $25.42 | 2025 | Fyarro |
| Aveo Pharmaceuticals, INC. | $23.92 | 2023 | Fotivda |
| Accord Healthcare, INC. | $20.61 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $20.17 | 2019 | |
| Partner Therapeutics, INC. | $20.09 | 2019 | |
| Tempus Ai, INC | $19.69 | 2024 | |
| Tesaro, INC. | $18.26 | 2019 | |
| Kyowa Kirin, INC. | $18.00 | 2025 | |
| Advanced Accelerator Applications | $16.66 | 2020 | |
| Sirtex Medical INC | $14.93 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$93.58 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marin Xavier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.